On August 20, 2026, Femtech Insider reported that fertility supplement and at-home testing brand Bird&Be has partnered with Mandell's Clinical Pharmacy, a 24/7 nationwide specialty fertility pharmacy, which will recommend Bird&Be's supplements to its network of fertility patients and clinics. The framing from both sides is access: roughly half of U.S. counties have no OB/GYN coverage, and about one in six couples experience infertility.

Why It Matters

Supplements are the softest part of the femtech stack — unregulated claims, low barriers to entry, and consumer skepticism that has only grown. Clinical distribution is the credibility arbitrage: a pharmacist recommendation does work that no amount of DTC marketing spend can buy, and it insulates a brand from the platform advertising restrictions that hammer sexual and reproductive health categories. If Bird&Be's referral channel keeps compounding at anything near 200% YoY, expect competitors in fertility, menopause, and sexual wellness supplements to start chasing pharmacy and clinic partnerships as their primary growth motion rather than a nice-to-have.

The interesting number in the announcement isn't the partnership itself but the channel data behind it. Bird&Be says clinician referrals are up 200% year over year and now account for more than 10% of its customers. That is a meaningful shift for a brand that built itself on direct-to-consumer supplements, and it lands alongside a retail expansion into 1,000 Ulta Beauty locations. The company is running a three-channel strategy simultaneously — DTC, mass beauty retail, and clinical referral — which is unusual for a category where most players pick one and defend it.

Co-founder and CEO Samantha Diamond positioned the deal around treatment-adjacent nutrition: patients already in IVF or IUI cycles, buying through the pharmacy that fills their prescriptions, picking up supplements at the same touchpoint. That is a materially different customer than the pre-conception DTC buyer, and it comes with a different trust dynamic — the pharmacist is the recommender rather than an Instagram ad.

The move fits a broader 2026 pattern in femtech where consumer brands are climbing back up the clinical stack rather than trying to disintermediate it. It's the same logic behind Willow pushing breastfeeding kits into hospital discharge bags and Kiara Health building tooling for the pre-treatment fertility window: the growth is in becoming part of the care pathway, not in competing with it for attention.

Sources

Update — 2026-08-21

Initial entry — story first created.